Browse the evidence

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces substantial, clinically meaningful, and sustained weight reduction in adults with obesity (BMI ≥30 or ≥27 with comorbidities) when used as an adjunct to lifestyle intervention, demonstrating superior efficacy compared to selective GLP-1 receptor agonists.

If you have obesity (BMI ≥30, or ≥27 with health issues like high blood pressure or sleep apnea), tirzepatide is a once-weekly injection that works by mimicking gut hormones (GIP and GLP-1) to help you lose weight. It is used alongside a reduced-calorie diet and exercise. The dose starts low (2.5 mg) and increases every 4 weeks to minimize stomach issues, reaching up to 15 mg. Clinical trials are designed to show it causes more weight loss than older drugs like semaglutide.

Combination anti-obesity medications (AOMs) are more effective than monotherapy for treating weight regain after bariatric surgery, with patients prescribed three or more AOMs losing significantly more weight than those on one.

If you have regained weight after bariatric surgery, taking just one weight-loss medication may not be enough. This study suggests that using a combination of anti-obesity medications, along with lifestyle changes, leads to significantly greater weight loss than using a single medication. Talk to your doctor about whether a combination approach is right for you, keeping in mind that access and cost can be barriers.

A 4-week low-carbohydrate diet (25% carbs, 45% protein, 30% fat) significantly reduces body weight, BMI, and body fat in obese adults while shifting gut microbiota composition by decreasing Firmicutes and increasing Bacteroidetes.

Adopt a low-carbohydrate diet for 4 weeks, aiming for 25% carbs, 45% protein, and 30% fat. Calculate your daily calories based on your ideal body weight (ideal weight in kg multiplied by 20-25, then by 0.75). Focus on high-protein foods, non-starchy vegetables, and use meal replacements if needed to stay on track. Drink at least 1.8 liters of water daily. This approach has been shown to significantly reduce body weight, BMI, and body fat, while improving gut microbiota diversity.

Long-term treatment with semaglutide 2.4 mg (up to 68 weeks) produces significant weight loss (mean 14.5-14.8%) and improves cardiometabolic biomarkers (blood pressure, HbA1c, LDL, triglycerides) in real-world patients with obesity or overweight.

If you have obesity or overweight with a related health condition, semaglutide 2.4 mg taken once weekly can lead to significant weight loss (around 15% of body weight) and improvements in blood pressure, blood sugar, and cholesterol over a year. This is based on real-world data from thousands of patients, suggesting it works effectively outside of strict clinical trial settings. You must be willing to stay on the medication for at least a year to see these full benefits.

A digitally enabled, time-restricted eating (TRE) program combined with low-carbohydrate intake and behavioral support leads to clinically significant weight loss (mean 9.2%) and improved glycemic control in overweight/obese adults, with effects sustained at 12 months.

If you are overweight or obese, a structured program combining time-restricted eating (like 16:8), lower carbohydrate intake, and regular support from a clinician and peer mentor can lead to significant, sustained weight loss (around 9%) and better blood sugar control over a year. It is important to have professional support to manage the behavioral aspects and ensure safety.

In overweight or obese adults, tirzepatide produces significantly greater weight loss than semaglutide over a 6-month period, particularly in patients without diabetes.

If you are overweight or obese and considering medication, tirzepatide appears to offer greater weight loss benefits than semaglutide over a 6-month period, especially if you do not have diabetes. However, real-world effectiveness can vary based on adherence and cost, so discuss these factors with your provider.

Individualized Virtual Integrative Medicine (IVIM) protocol combined with tirzepatide results in significant weight loss (mean -52.28 lbs at 52 weeks) and high treatment adherence (99.36% achieving >5% weight loss) compared to standard care models.

If you have obesity (BMI >= 30) and are starting tirzepatide, consider a program that offers flexible dosing and regular telehealth support. This approach allows you to adjust your dose based on side effects and progress, rather than following a rigid schedule. Most patients in this study lost significant weight (over 20 lbs on average at 52 weeks) without needing the highest dose, and compounded versions worked just as well as branded ones. The key is consistent support and personalized adjustments.

Skeletal muscle mass can be preserved during significant weight loss induced by incretin-based medications if the patient adheres to a program involving twice-weekly strength training and adequate protein intake (60-90 g/day).

To prevent muscle loss while losing weight with these medications, you must actively train. Perform strength training at least twice a week and ensure you are eating 60-90 grams of protein daily. This combination helps stabilize your muscle mass after the initial months of weight loss.

The Adaptive Ketogenic–Mediterranean Protocol (AKMP) significantly improves insulin resistance, remnant cholesterol, and body composition in adults with overweight or obesity over a 14-week period.

Follow a 14-week plan starting with very low carbs (≤20g/day) and high healthy fats (olive oil, fish) to reset insulin sensitivity and burn fat. After 12 weeks, gradually add back carbs (>100g/day) while maintaining a Mediterranean diet structure. Monitor your progress and adjust protein or calories if weight loss stalls.

Oral nutritional supplements (ONS) containing high-quality protein and micronutrients are an effective strategy to prevent nutrient deficiencies and support muscle health in patients with reduced appetite from IMDs.

If you can't eat enough protein due to nausea or fullness from your medication, use oral nutritional supplements (ONS) to fill the gap. Choose products specifically designed for muscle health, not just isolated vitamin pills.

Combined resistance and moderate-intensity aerobic exercise improves functional capacity, muscle strength, and quality of life in post-COVID-19 patients after hospital discharge.

If you are recovering from COVID-19 after hospital discharge, start with a combination of light resistance training (1-2 sets of 8-10 reps at 30-80% of your max) and moderate aerobic exercise (5-30 minutes). Focus on feeling comfortable (RPE 3-5/10) rather than pushing hard. This approach has been shown to improve your ability to walk, your muscle strength, and your overall quality of life without significantly increasing the risk of reinfection.

High-dose mazdutide (9-10 mg once-weekly) produces robust, statistically significant body weight loss (approx. 10-12%) in Chinese adults with overweight or obesity, with a favorable safety profile despite transient gastrointestinal side effects.

If you are an adult with overweight or obesity, once-weekly injections of mazdutide (9-10 mg) can lead to significant weight loss (around 10%) over 3-4 months. While you may experience temporary stomach issues like nausea or diarrhea, these usually improve over time. This treatment is most effective when combined with maintaining your current diet and exercise habits.

Phenotype-tailored lifestyle interventions (PLI) result in significantly greater weight loss (-7.4 kg) compared to standard lifestyle interventions (SLI, -4.3 kg) in adults with obesity over a 12-week period.

To maximize weight loss, identify your specific obesity phenotype (e.g., abnormal satiation, emotional eating, or low energy expenditure) through professional assessment. Then, follow a tailored plan that combines a 500-calorie daily deficit with specific behavioral or exercise strategies (like pre-meal protein or HIIT) designed for your phenotype, rather than a generic diet.

Precision nutrition (PN) interventions, which tailor dietary recommendations based on individual genetic profiles, gut microbiota composition, and lifestyle factors, are more effective at improving diet quality, adherence, and metabolic outcomes in obesity management than generalized dietary guidelines.

Instead of following generic diet trends, seek a precision nutrition approach that considers your unique genetic markers and gut health. This may involve specific testing to tailor your macronutrient intake (e.g., high-protein for certain genotypes, specific fiber types for microbiota balance) to your body's actual metabolic response, rather than a one-size-fits-all restriction.

Adjunct treatment with once-weekly semaglutide (up to 1.0 mg) produces sustained, clinically significant weight loss (mean 14.7% total weight loss) in post-bariatric patients with weight regain or insufficient weight loss over 12 months, regardless of sex or initial surgery type.

If you have regained weight or lost insufficient weight after bariatric surgery, semaglutide (a GLP-1 medication) can help you lose more weight, even if you don't have diabetes. In this study, patients lost an average of 14.7% of their body weight over a year using a dose lower than the maximum approved for obesity. This offers a medical option when lifestyle changes alone are not enough, potentially avoiding the need for revision surgery.

Sustained weight loss of 10% or more through combinatorial lifestyle, medical, or surgical interventions is the most effective strategy for preventing hepatocellular carcinoma (HCC) by reversing or halting the progression of metabolic dysfunction-associated fatty liver disease (MAFLD).

To lower your risk of liver cancer, you need to reduce your body weight by at least 10%. This is best achieved by combining a calorie-restricted diet (focusing on plants and limiting sugars/fats) with regular exercise (150 minutes/week). If lifestyle changes aren't enough, medical therapies or bariatric surgery are highly effective options that provide durable weight loss and reverse liver disease. The goal is sustained weight reduction, not just short-term dieting.

Combining GLP-1 receptor agonists (specifically liraglutide) with bariatric surgery (BS) or endoscopic bariatric therapy (EBT) significantly enhances weight loss and metabolic improvements compared to BS or EBT alone, particularly in patients experiencing weight regain or insufficient loss.

If you have had bariatric surgery or an endoscopic procedure but are regaining weight or hitting a plateau, adding a GLP-1 receptor agonist like liraglutide (titrated to 3mg daily) can significantly boost weight loss and metabolic health compared to the procedure alone. This is particularly effective for those who have regained weight after surgery. Expect potential gastrointestinal side effects like nausea, which often subside with dose titration. This approach is not a replacement for lifestyle changes but a powerful adjunct to them.

Ensuring adequate protein intake at every eating occasion is essential to prevent loss of lean body mass and malnutrition during rapid weight loss induced by GLP-1 RAs.

Because GLP-1 medications suppress appetite, you may struggle to eat enough. Prioritize protein at every meal to protect your muscles. If you can only eat small amounts, choose high-protein foods. Consider liquid protein sources if solid food is unappealing.

To maximize muscle hypertrophy, resistance training should utilize a repetition tempo with a total duration between 2 and 8 seconds per repetition, regardless of the specific distribution of time between eccentric and concentric phases.

When performing resistance exercises, aim for each repetition to take between 2 and 8 seconds total. You do not need to obsess over whether the lowering (eccentric) or lifting (concentric) phase is longer, as long as the total time falls within this window. Control the weight, but do not slow down excessively (e.g., 'super slow') as this may be detrimental.

High frequency of self-monitoring (meal logging) and self-management (task completion) in the early stages of a blended-care intervention is positively associated with weight loss at 6 and 12 months, indicating that early adherence drives long-term success.

Start logging your meals and completing your daily tasks immediately. The data shows that this early effort is a strong predictor of weight loss at 6 and 12 months, even if you don't see immediate results.

Adding GLP-1 receptor agonists (GLP1RAs) to metformin effectively improves anthropometric measures (weight, BMI, waist circumference, waist-to-hip ratio) in women with PCOS.

For PCOS patients struggling with weight, adding a GLP-1 receptor agonist (like semaglutide or liraglutide) to metformin is a highly effective strategy for reducing body weight and waist circumference, addressing the core metabolic driver of the syndrome.

Resistance training (RT) significantly improves body composition (muscle mass) and grip strength in elderly patients with sarcopenia following hip replacement surgery, regardless of HMB supplementation.

Start resistance training after hip surgery as soon as medically cleared. Begin with lighter weights (60-70% of your max) and gradually increase to heavier weights (80-90%) over 3 months. This builds muscle and strength, which helps prevent falls and improves daily function.

For patients on GLP-1 receptor agonists, adequate protein intake and strength training are necessary to mitigate muscle mass loss associated with rapid weight loss, while dietary adjustments (smaller, lower-fat meals, fiber) help manage gastrointestinal side effects.

If you are taking GLP-1 medication, prioritize protein and strength training to protect your muscles. Manage GI side effects by eating smaller, lower-fat meals and using fiber supplements if needed. Avoid high-intensity exercise if it exacerbates nausea or diarrhea.

A 9-month intensive lifestyle intervention (dietary modification and increased physical activity) produces significant short-term weight loss and improved glycemic control in young women with prior gestational diabetes and newly diagnosed type 2 diabetes, with weight loss effects persisting for at least 6 years.

If you are a young woman with a history of gestational diabetes who has recently been diagnosed with type 2 diabetes, committing to a structured 9-month lifestyle program can help you lose about 4% of your body weight and improve your blood sugar control. Key steps include reducing daily calorie intake by roughly 200-240 calories, limiting fat to less than 30% of your diet, eating 20-30g of fiber daily, and exercising moderately for 30 minutes every day. Even after the program ends, the weight loss benefit can last for at least 6 years, though blood sugar control may require ongoing attention.